Ultrasound monitoring of testis and prostate maturation in hypogonadotropic hypogonadic males during gonadotropin-releasing hormone treatment.

The effects of the administration of gonadotropin-releasing hormone (GnRH) on the increase of testis and prostate volume was monitored by ultrasound in six patients affected by idiopathic hypogonadotropic hypogonadism. A significant increase of testis volume was observed after 90 and 180 days (6.65 versus 3.32 mL, 99.1% net increase and 8.47 mL, 176.8% increase, respectively) of pulsatile GnRH treatment. A similar increase of prostate volume was observed at day 90 (12.67 versus 7.78 mL, 70.3% net increase) and day 180 (14.70 mL, 97.7% increase). The ultrasound monitoring of the modifications of testis and prostate volume may represent a biological assay of the effects of GnRH treatment and offer additional data on the response of target organs to the hormonal treatment.

Modification of the 1,2,3-triazole ring present in an effective in vitro inhibitor of the prostaglandin synthesis.

This paper describes some modifications of the heterocyclic ring of 1-N-benzylsubstituted 1,2,3-triazoles, which are effective inhibitors of the arachidonic acid-induced malondialdehyde production in human platelets. The corresponding 1-N-imidazole- or 1-N-1,2,4-triazole-derivatives, with basic properties, preserve the inhibitory enzymatic activity, whilst the C-substituted tetrazole or 1,3,4-oxadiazole derivatives, with a neutral character, show no activity. A close structural relationship between our active compounds and Dazoxiben, a potent selective tromboxane-synthetase inhibitor, was observed.

[Treatment of male genital infections with enoxacin]. / Trattamento delle flogosi genitali maschili con enoxacina.

Inflammatory disease such as prostatitis and prostatovesiculitis, can affect the fertility potential of the male population. In this study, the Authors tested the therapeutical efficacy of a second generation quinolone, enoxacin, in patients suffering from vesicular and/or prostatic inflammations. This drug has been shown to diffuse into the prostatic fluid, achieving therapeutical concentrations either in acute or chronic pathological conditions. Thirty infertile patients referring to our Andrology Center and showing seminal signs (leukocytes, abnormal sperm forms, chemical and physical alterations, etc) of genital tract inflammations were found to have positive sperm culture for enoxacin-sensitive strains. Further investigations (echotomography) showed that they were affected by prostatic and/or vesicular subacute chronic inflammations. The mean age was 32.2 (range 20-36) ys. All the patients discontinued any previous treatment for at least 90 days. Enoxacin was administered at the dose of 300 mg b.i.d. for two cycles of 10 days each, with intervals of 20 days. At the beginning and at the end of the treatment (days 0 and 60), semen analysis and culture were performed. A paired-T test was employed for the statistical evaluation of data. 26.6% of patients ad an altered fluidification before treatment. Only 10.0% of them showed the same sign after treatment. A condition of hyperviscosity was present in 50% and 16.6% of patients before and after treatment respectively. Likewise, an elevated number of leukocytes (greater than 10(6)/ml) occurred in the ejaculates of 43.3% of patients and in 23.3% after enoxacin treatment. Enoxacin treatment was efficacious in 89.2% of cases, in presence of either Gram positive or Gram negative bacteria.(ABSTRACT TRUNCATED AT 250 WORDS)